You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on KRAS biomarkers.
In PNAS this week: possible treatment targets in KRAS-mutated lung cancer, transcriptional analysis of mouse models lacking a p53 inhibitor, and more.
Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.
Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
Biocartis' Idylla called some colorectal cancer samples negative that Sysmex Inostics's OncoBEAM called positive, but the clinical implications may be complex.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
Researchers used a genome-scale CRISPRi platform to identify genetic interactions with an inhibitor for a mutant form of KRAS in models of lung and pancreatic cancer.
Howard Hughes Medical Institute will be requiring its researchers to publish their work so it is immediately accessible to the public, ScienceInsider writes.
The Huffington Post reports that Francis Collins, the director of the US National Institutes of Health, has urged Americans to recommit to reason.
About 150 million rapid coronavirus tests purchased by the US federal government are to be distributed to nursing homes, colleges, and the states, according to the New York Times.
In Nature this week: multi-omic analysis of Alzheimer's disease brain samples, de novo assembly of a diploid potato, and more.